ESMO Gynaecological Cancers Congress 2024: Abstracts
The abstract submission will open soon
The abstract submission will open soon
ACS CAN is the leading cancer advocacy organization that is working every day to make cancer issues a national priority.
PURPOSE Standard therapy for locally advanced non–small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that…
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers…
Treatment with loncastuximab tesirine yielded high response rates in patients with relapsed or refractory marginal zone lymphoma.
Tune in to this VJHemOnc podcast to hear experts Ola Landgren, Suzanne Lentzsch, Suzanne Trudel and Thomas Martin discuss updates with various agents in myeloma.
Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
RLYB331 is a human antibody that increases hepcidin, reduces iron overload, and ameliorates ineffective erythropoiesis in β-thalassemiaCombination with RAP
The OncoAlert Newsletter is now out for June 23-29, 2023
2233 S Martin Luther King Dr Chicago, IL 60616 Join Healio | HemOnc Today as we celebrate the risk-takers and groundbreakers at this prestigious awards…